Completed PHASE3 INTERVENTIONAL 2-arm NCT06469411

Effect of PMSCs and Their Secretome for the Treatment of GvHD (GvHD)

The Effect MSCs Derived From the Placenta and Their Secretome for the Treatment of GvHD: A Randomized Clinical Trial

Sponsor: SCARM Institute, Tabriz, Iran

Conditions GVHD

Interventions 4 cc distilled water dissolved in albumin 20% Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)

Updated 3 times since 2024 Last updated: Jun 19, 2024 Started: Jan 1, 2023 Primary completion: Jun 30, 2023 Completion: Jan 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on GVHD, this trial is completed. The trial is conducted by SCARM Institute, Tabriz, Iran and has accumulated 3 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SCARM Institute, Tabriz, Iran
Tabriz University of Medical Sciences

Data source: Tabriz University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tabriz, Iran